We are live on ! Find out more
LLY icon

Eli Lilly

2,814 hedge funds and large institutions have $367B invested in Eli Lilly in 2023 Q2 according to their latest regulatory filings, with 297 funds opening new positions, 1,072 increasing their positions, 1,079 reducing their positions, and 77 closing their positions.

New
Increased
Maintained
Reduced
Closed

286% more first-time investments, than exits

New positions opened: 297 | Existing positions closed: 77

59% more funds holding in top 10

Funds holding in top 10: 153243 (+90)

36% more capital invested

Capital invested by funds: $270B → $367B (+$96.8B)

8% more funds holding

Funds holding: 2,6142,814 (+200)

1% less repeat investments, than reductions

Existing positions increased: 1,072 | Existing positions reduced: 1,079

8% less call options, than puts

Call options by funds: $3.39B | Put options by funds: $3.68B

5.84% less ownership

Funds ownership: 88.48%82.64% (-5.8%)

Holders
2,814
Holders Change
+200
Holders Change %
+7.65%
% of All Funds
44.18%
Holding in Top 10
243
Holding in Top 10 Change
+90
Holding in Top 10 Change %
+58.82%
% of All Funds
3.82%
New
297
Increased
1,072
Reduced
1,079
Closed
77
Calls
$3.39B
Puts
$3.68B
Net Calls
-$288M
Net Calls Change
-$424M
Name Holding Trade Value Shares
Change
Change in
Stake
N
151
Natixis
France
$164M +$125M +298,949 +585%
MSV
152
MN Services Vermogensbeheer
Netherlands
$163M -$23.1M -55,200 -14%
Public Sector Pension Investment Board (PSP Investments)
153
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$161M +$37.2M +88,657 +35%
AT
154
AMF Tjänstepension
Sweden
$159M -$39.2M -93,381 -22%
CS
155
Candriam SCA
Luxembourg
$159M -$60.8M -145,090 -30%
Lazard Asset Management
156
Lazard Asset Management
New York
$158M -$15.9M -37,846 -10%
William Blair & Company
157
William Blair & Company
Illinois
$155M +$5.3M +12,633 +4%
Commonwealth Equity Services
158
Commonwealth Equity Services
Massachusetts
$155M +$134K +319 +0.1%
Mirae Asset Global Investments
159
Mirae Asset Global Investments
South Korea
$154M -$30.7M -73,225 -18%
BFC
160
Bedel Financial Consulting
Indiana
$151M -$117K -279 -0.1%
Mackenzie Financial
161
Mackenzie Financial
Ontario, Canada
$149M +$22.4M +53,501 +20%
GT
162
Glenmede Trust
Pennsylvania
$149M
BNP Paribas Financial Markets
163
BNP Paribas Financial Markets
France
$149M -$88.9M -211,990 -40%
GGHC
164
Gilder Gagnon Howe & Co
New York
$149M +$9M +21,450 +7%
HNB
165
Huntington National Bank
Ohio
$149M +$15.3M +36,448 +13%
WAM
166
Weatherly Asset Management
California
$143M -$921K -2,195 -0.7%
AQR Capital Management
167
AQR Capital Management
Connecticut
$142M -$11.3M -27,007 -8%
CAPTRUST Financial Advisors
168
CAPTRUST Financial Advisors
North Carolina
$142M -$28.5M -67,925 -18%
PHS
169
PFM Health Sciences
California
$140M
WP
170
Woodline Partners
California
$138M +$78.7M +187,624 +175%
SAI
171
Systematic Alpha Investments
New Jersey
$131M
OFG
172
Oxford Financial Group
Indiana
$131M +$38.3M +91,339 +49%
CAM
173
Congress Asset Management
Massachusetts
$130M -$859K -2,048 -0.7%
NAM
174
Nissay Asset Management
Japan
$128M -$11.6M -27,566 -9%
Osaic Holdings
175
Osaic Holdings
Arizona
$124M -$3.44M -8,212 -3%

LLY Hedge Fund Activity: Q2 2023 in Review

2,814 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q2 2023, worth a combined $367B — up 36% from $270B a quarter earlier.

Buyers outnumbered sellers: 297 funds opened new LLY positions and 77 closed out — a net gain of 220 holders — while 1,072 added to existing stakes and 1,079 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $1.35B. The largest seller was OFI Invest Asset Management, cutting an estimated $22.2B.

  • 2,814 institutional investors held Eli Lilly (LLY) as of Q2 2023, up from 2,614 in Q1 2023.
  • Funds reported $367B of Eli Lilly stock for Q2 2023, up 36% quarter-over-quarter.
  • 297 funds opened new Eli Lilly positions in Q2 2023 and 77 closed out, a net change of +220 holders.
  • The largest Eli Lilly buyer in Q2 2023 was JP Morgan Chase, an estimated $1.35B added.
  • The largest Eli Lilly seller in Q2 2023 was OFI Invest Asset Management, an estimated $22.2B sold.

Based on aggregated 13F filings for Q2 2023.